promising treatment of long covid

long covid symptom groups

low dose naltrexone

patients and market

Chronic fatigue-like syndrome, headache;

 

Cognitive symptoms: deficits in working memory and executive functioning, deficits in spatial planning, difficulty with word retrieval and fluency, and impaired attention (commonly referred to as brain fog);

 

Respiratory syndrome (cough and difficulty breathing);

 

Chronic pain;

 

Neurosensorial syndrome (altered sense of taste and smell);

 

Naltrexone, a competitive opioid receptor antagonistic, was approved by the FDA in 1984 in a 50mg dose for the purpose of helping patients with heroin or opium addiction.

 

At low doses (between 1-5 mg) naltrexone has analgesic and anti-inflammatory properties.

 

Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Jeremijenko A, Griffin P and Marshall-Gradisnik S (2024) Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target. Front. Immunol. 15:1264702. doi: 10.3389/fimmu.2024.1264702

 

 

 

 

COVID-19 is characterized by dysregulation of the immune system, with evidence of hyperinflammation.

 

Randomized clinical trial is needed to confirm safety and efficacy of low dose naltrexone in the treatment of cognitive symptoms related to infection with SARS-CoV-2 where alternative explanation for symptoms cannot be found.

 

Worldwide, there are 36 millions of patients with Long COVID symptoms

 

There are several hypothesized mechanisms for long COVID pathogenesis, including immune dysregulation (complement dysregulation), microbiota disruption, autoimmunity, clotting and endothelial abnormality, and dysfunctional neurological signaling.

 

info@low-dose-naltrexone.com

 

RATIONALE

..neoversum consulting

CONTACT